Read More Pharma Industry News Dimerix stock up 74% YTD as FSGS asset DMX-200 gets safety green light Dimerix’s FSGS drug candidate DMX-200 clears key Phase 3 safety review with no concerns. Learn how this ASX biotech aims to reshape kidney disease treatment. byPallavi MadhirajuMay 22, 2025